江西一脉阳光集团股份有限公司是一家主要从事医学影像专科医疗业务的中国公司。该公司主要提供医 学影像服务及解决方案。该公司经营三个分部。影像中心服务通过旗舰型影像中心为患者及其他医疗保 健消费者提供影像检查及诊断服务。影像解决方案服务主要帮助医院等医疗机构客户选择及采购满足他 们发展需要的合适影像设备，以及提供一系列配套模块化解决方案。一脉云服务为影像中心服务业务发 展、信息化管理及数据驱动运营提供支撑。 证券之星消息，2月27日南向资金增持98.45万股一脉阳光（02522.HK）。近5个交易日中，获南向资金 增持的有2天，累计净增持24.4万股。近20个交易日中，获南向资金增持的有11天，累计净增持379.15万 股。截至目前，南向资金持有一脉阳光（02522.HK）1.43亿股，占公司已发行普通股的48.58%。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 ...

Core Viewpoint - Southbound funds have significantly increased their holdings in Yipai Sunshine (02522.HK), indicating strong investor interest in the company [1] Group 1: Southbound Fund Activity - On February 10, southbound funds increased their holdings by 265,000 shares in Yipai Sunshine (02522.HK) [1] - Over the past 5 trading days, there have been 4 days of net increases in holdings, totaling 2,194,500 shares [1] - In the last 20 trading days, there were 13 days of net increases, amounting to 9,660,500 shares [1] - Currently, southbound funds hold 14.3 million shares of Yipai Sunshine, representing 48.49% of the company's issued ordinary shares [1] Group 2: Company Overview - Jiangxi Yipai Sunshine Group Co., Ltd. primarily engages in specialized medical imaging services in China [1] - The company offers medical imaging services and solutions through three main divisions [1] - The Imaging Center Services provide imaging examinations and diagnostic services to patients and healthcare consumers [1] - The Imaging Solutions Services assist hospitals and medical institutions in selecting and procuring suitable imaging equipment, along with providing modular solutions [1] - Yipai Cloud Services support the development of imaging center services, information management, and data-driven operations [1]

Core Viewpoint - Southbound funds reduced their holdings in Yimai Sunshine (02522.HK) by 71,000 shares on February 9, while there were net increases in holdings for 3 out of the last 5 trading days, totaling 1.702 million shares. Over the last 20 trading days, there were net increases for 12 days, amounting to 7.445 million shares [1] Company Overview - Jiangxi Yimai Sunshine Group Co., Ltd. is primarily engaged in specialized medical imaging services in China. The company offers medical imaging services and solutions [1] - The company operates through three segments: Imaging Center Services, Imaging Solutions, and Yimai Cloud Services. Imaging Center Services provide imaging examinations and diagnostic services to patients and healthcare consumers through flagship imaging centers [1] - Imaging Solutions assist hospitals and other medical institutions in selecting and procuring suitable imaging equipment to meet their development needs, along with providing a range of modular solutions [1] - Yimai Cloud Services support the development of imaging center services, information management, and data-driven operations [1]

Core Viewpoint - The insurance industry is transitioning from traditional risk compensation to a comprehensive health management service model, focusing on prevention, intervention, and claims, as exemplified by the strategic partnership between Century Life Insurance Co., Ltd. and Panoramic Medical Imaging Technology Co., Ltd. [1][4] Group 1: Strategic Cooperation - The strategic signing ceremony took place on January 16, 2026, in Shanghai, marking the beginning of a deeper collaboration between the two companies [2] - The partnership aims to integrate advanced medical imaging technology and health screening services into insurance offerings, emphasizing early disease detection and prevention [4] Group 2: Value Reconstruction - The collaboration reflects a shift in health protection philosophy, moving from post-event compensation to proactive prevention and early intervention [4] - Century Life is restructuring its service model to focus on the entire customer lifecycle, integrating prevention, protection, and service [4] Group 3: Health Management Services - Panoramic Medical has over a decade of experience in high-end medical services, focusing on cancer and cardiovascular disease diagnostics, and offers a range of health management services [6] - The partnership combines professional medical services with quality insurance, creating a comprehensive health management and risk protection system [6] Group 4: Industry Benchmarking - The collaboration is seen as a response to the call for technological finance and inclusive finance, aiming to make advanced medical technology accessible to a broader population [8] - The goal is to reduce the burden of major diseases on individuals and society, contributing to the vision of a "Healthy China" and promoting longevity [8] Group 5: Company Overview - Century Life Insurance was established on June 3, 2009, and has expanded to 20 provincial branches and over 370 sub-branches across more than 150 major cities in China [9] - As of December 2024, the company has total assets nearing 280 billion yuan and has paid out over 11.2 billion yuan in claims, providing significant insurance and health services to millions [9]

Core Viewpoint - The China Securities Regulatory Commission (CSRC) has disclosed that five companies have recently obtained approval for overseas issuance and listing or full circulation of unlisted shares in China, all targeting the Hong Kong Stock Exchange and are in the process of secondary applications [1] Group 1: Company Summaries - Stone Technology, once known as a "sweeping broom" in the A-share market, saw its stock price peak at 1494.99 yuan per share in June 2021, with a market capitalization of 99.266 billion yuan, but has since decreased to a total market value of 42.361 billion yuan, representing a decline of over 50%. The company plans to issue no more than 33.108 million shares [1] - Haizhi Technology, an AI application company founded by former Baidu executives and backed by Hillhouse Capital, focuses on products like the Atlas mapping solution and Atlas intelligent agents. It intends to issue no more than 47.5846 million shares and convert 372 million shares held by shareholders into H-shares [1] - Yushi Technology specializes in L4-level autonomous driving technology, with investors including Innovation Works. The company plans to issue no more than 18.9142 million shares and convert 112 million shares held by shareholders into H-shares [1] - Deshi Biotech aims to become the first company to launch a medical imaging large model, planning to issue no more than 31.004 million shares and convert 80.88 million shares held by shareholders into H-shares [1] - Shangmi Technology, a provider of commercial IoT (BIoT) solutions with shareholders including Ant Group, Meituan, and Xiaomi, plans to issue no more than 46.004 million shares and convert 261 million shares held by shareholders into H-shares [1]

Group 1 - The core point of the article highlights that southbound funds increased their holdings in Yipai Sunshine (02522.HK) by 1.022 million shares on January 8, while experiencing a net reduction of 0.887 million shares over the last five trading days [1] - Over the past 20 trading days, Yipai Sunshine faced net reductions in holdings for 10 days, totaling 3.7445 million shares [1] - Currently, southbound funds hold 13.3 million shares of Yipai Sunshine, representing 45.1% of the company's total issued ordinary shares [1] Group 2 - Yipai Sunshine Group Co., Ltd. is primarily engaged in specialized medical imaging services in China [1] - The company offers medical imaging services and solutions through three main divisions: imaging center services, imaging solutions, and Yipai cloud services [1] - The imaging center services provide diagnostic imaging examinations to patients and healthcare consumers, while imaging solutions assist hospitals in selecting and procuring suitable imaging equipment [1]

Group 1 - The core message of the event is the potential for collaboration between South Korean and Chinese startups, particularly in the fields of artificial intelligence and smart hardware, as emphasized by MiniMax's founder Yan Junjie [1] - The South Korean government, represented by President Yoon Suk-yeol, expressed strong support for fostering exchanges and collaborations between the two countries' entrepreneurial ecosystems [3] - The forum highlighted the significant interest from South Korean startups in entering the Chinese market, with many companies seeking partnerships to leverage China's vast market potential [1][3] Group 2 - LUNIT's CEO Xu Banshi called for the establishment of a Sino-Korean startup group to collaboratively build a data center and conduct data validation work, aiming to identify cooperative projects [2] - CMBI's CEO Huo Jianjun suggested that South Korean companies leverage their semiconductor technology advantages in conjunction with Chinese market applications to create substantial synergies [2] - The event showcased over 50 Korean beauty brands, indicating a strong interest in the Chinese beauty market, with the First Lady of South Korea praising the diversity and responsiveness of these brands to market demands [3]

Core Viewpoint - The China Securities Regulatory Commission has approved the overseas listing of Hangzhou Deshi Biotechnology Co., Ltd., allowing the company to issue up to 31.04 million shares for listing on the Hong Kong Stock Exchange, while 27 shareholders will convert a total of 80.88 million domestic unlisted shares into overseas listed shares [1] Group 1: Company Overview - Deshi Biotechnology is a leading enterprise in the field of medical imaging AI and medical imaging equipment, with a global market presence [1] - The company has developed a diversified product matrix based on its self-developed general medical imaging base model, iMedImage, including systems for chromosome karyotype analysis and automatic cell imaging [1] - In 2024, Deshi Biotechnology achieved a market share of 30.6% in China's chromosome karyotype analysis sector, ranking first and breaking the long-standing monopoly of imported brands [1] Group 2: Market Position and Recognition - The company has established a customer base covering over 400 medical care centers and institutions across China, gaining widespread market recognition [1] - In 2025, Deshi Biotechnology was selected for the 11th batch of the "Excellent Domestic Medical Equipment Product Catalog" due to its technological innovation and clinical value [1] Group 3: Future Plans - The company plans to continue providing standardized intelligent imaging equipment, a Model-as-a-Service (MaaS) cloud platform, and localized self-training solutions to enhance the efficiency, accuracy, and accessibility of medical imaging diagnostics [2] - Deshi Biotechnology aims to lead the global medical imaging industry into an era of intelligence through technological innovation [2]

Core Viewpoint - Deshi Biotechnology has submitted a listing application to the Hong Kong Stock Exchange, with Huatai International as the sole sponsor [1] Company Overview - The company focuses on developing medical imaging products and services, with a product portfolio that includes six medical imaging software (including the core product AI AutoVision® and commercial product AutoVision®), three commercial medical devices, and four main reagent consumables [1] Key Product Information - The core product AI AutoVision® is a chromosome karyotype auxiliary diagnostic software that utilizes AI functionalities for intelligent analysis in prenatal diagnosis of birth defects and assisted reproductive diagnosis, demonstrating high sensitivity and specificity in multi-center clinical trials (e.g., sensitivity of 100.00% for detecting abnormal numbers, specificity of 100.00%) [1] Market Outlook - The intelligent medical imaging detection market is projected to grow significantly, with the global market expected to increase from $1.6 billion in 2024 to $25.1 billion by 2035, and the Chinese market anticipated to grow from RMB 2.4 billion in 2024 to RMB 78.1 billion by 2035, indicating a rapid growth trend [1]

Core Viewpoint - The 18th China Industrial Forum emphasizes the theme "Integration and Innovation, Strengthening Industry," highlighting the transformative impact of artificial intelligence (AI) on various sectors, particularly in biomedicine and medical imaging [1][3]. Group 1: Artificial Intelligence Insights - AI is described as a digital twin of the "brain," with large models serving as the core application carrier [1][3]. - Breakthroughs in natural language processing and multimodal integration are noted as key innovations driving AI's practical value [1][3]. - Continuous focus and application of AI are expected to bring significant benefits to production and daily life [1][3].